Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 115Carcinoma, Non-Small-Cell Lung 103Prostatic Neoplasms 90Neoplasms 74Multiple Myeloma 73Lung Neoplasms 64Colorectal Neoplasms 50Leukemia, Myeloid, Acute 46Neoplasm Metastasis 43Lymphoma 39Pancreatic Neoplasms 38Melanoma 38Lymphoma, Non-Hodgkin 36Carcinoma, Renal Cell 36Ovarian Neoplasms 34Leukemia, Lymphocytic, Chronic, B-Cell 33Squamous Cell Carcinoma of Head and Neck 31Urinary Bladder Neoplasms 30Hematologic Neoplasms 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Endometrial Neoplasms 26Uterine Cervical Neoplasms 25Carcinoma, Hepatocellular 25Triple Negative Breast Neoplasms 24Sarcoma 24Glioma 24Stomach Neoplasms 22Head and Neck Neoplasms 22Lymphoma, Large B-Cell, Diffuse 21Brain Neoplasms 21

Interventions

BF-200 ALA 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Keratosis, Actinic × 30 days × Clear all
NCT05662202 2026-05-22

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Biofrontera Inc.

Phase 3 Active not recruiting
172 enrolled
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡